-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
BioCrude Technologies USA, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from Q3 2022 to Q2 2024.
- BioCrude Technologies USA, Inc. Earnings Per Share, Diluted for the quarter ending June 30, 2024 was 0 USD/shares.
- BioCrude Technologies USA, Inc. Earnings Per Share, Diluted for the twelve months ending June 30, 2024 was 0 USD/shares.
- BioCrude Technologies USA, Inc. annual Earnings Per Share, Diluted for 2023 was 0 USD/shares.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)